紫杉醇脂质体联合顺铂治疗晚期食管癌的临床疗效研究

丁令池, 张晓东, 姚卫东, 陆俊国

丁令池, 张晓东, 姚卫东, 陆俊国. 紫杉醇脂质体联合顺铂治疗晚期食管癌的临床疗效研究[J]. 实用临床医药杂志, 2012, (21): 75-77.
引用本文: 丁令池, 张晓东, 姚卫东, 陆俊国. 紫杉醇脂质体联合顺铂治疗晚期食管癌的临床疗效研究[J]. 实用临床医药杂志, 2012, (21): 75-77.
DING Lingchi, ZHANG Xiaodong, YAO Weidong, LU Junguo. Clinical observation of paclitaxel liposome combined with cisplatin in the treatment of patients with advanced esophaeal cancer[J]. Journal of Clinical Medicine in Practice, 2012, (21): 75-77.
Citation: DING Lingchi, ZHANG Xiaodong, YAO Weidong, LU Junguo. Clinical observation of paclitaxel liposome combined with cisplatin in the treatment of patients with advanced esophaeal cancer[J]. Journal of Clinical Medicine in Practice, 2012, (21): 75-77.

紫杉醇脂质体联合顺铂治疗晚期食管癌的临床疗效研究

基金项目: 中国高校医学期刊临床专项资金
详细信息
  • 中图分类号: R735.1

Clinical observation of paclitaxel liposome combined with cisplatin in the treatment of patients with advanced esophaeal cancer

  • 摘要: 目的 探讨紫杉醇脂质体联合顺铂治疗晚期食管癌的临床疗效及安全性.方法 对38例患者随机分为试验组和对照组,试验组19例:紫杉醇脂质体135 mg/m2静脉滴注,第1天;顺铂25 mg/m2静脉滴注,第1~3天;对照组19例:氟尿嘧啶0.75/m2静脉滴注,第1~5天;顺铂25 mg/m2静脉滴注,第1~3天.21 d为1周期.结果 试验组与对照组有效率分别为49.65%和26.31%,2组比较有统计学意义(P<0.05).试验组及对照组中位疾病进展时间(mTTP)分别为4.6个月和3.7个月,中位生存期(mOS)分别为10.3个月和9.2个月,2组比较无统计学意义(P>0.05).2组在血液学毒性、消化道反应、周围神经毒性及脱发方面比较无统计学意义(P>0.05).结论 紫杉醇脂质体联合顺铂方案治疗晚期食管癌具有较好的疗效和安全性.
  • Bader F G, Lordick F, Fink U. Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I).A comparison of two phase Ⅱ trials with long-term follow-up [J]. Onkologie, 2008(7):366.
    苏丽, 张纬建, 洪金省. 食管癌三种放疗技术的剂量学比较 [J]. 实用临床医药杂志, 2010(9):37.doi: 10.3969/j.issn.1672-2353.2010.09.012.
    Vashi P G, Gupta D, Tan B. Colon Carcinoma with Unusual Metastasis to the Esophagus Manifesting as Multiple Nodules and Dysphagia:Management with Systemic Chemotherapy [J]. Case Rep Gastroenterol, 2012(2):484.
    Zhang X, Shen L, Li J. A phase Ⅱ trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinomaof the esophagus [J]. American Journal of Clinical Oncology, 2008(1):29.
    Huang J, Cai RG, MengPJ. Phase Ⅱ study of paclitaxel and cisplatin for advanced squamous cell carcinoma of esophagus [J]. Zhonghua Zhongliu Zazhi, 2004, (12):753.
    黄镜, 蔡锐刚, 孟平均. 紫杉醇联合顺铂治疗晚期食管鳞癌 [J]. 中华肿瘤杂志, 2004, (12):753.doi: 10.3760/j.issn:0253-3766.2004.12.014.
    Chen Q, Krol A, Wright A. Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome [J]. International Journal of Hyperthermia, 2008(6):475.
    Holvoet C, Vander H Y, Lories G. Preparation and evaluation of paclitaxel-containing liposomes [J]. Die Pharmazie, 2007(2):126.
    赵锐, 赵玮玮. 抗癌植物药紫杉醇研究进展与动态 [J]. 中草药, 2009(7):1172.
    Strieth S, Eichhorn M E, Werner A. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin [J]. Clinical Cancer Research, 2008, (14):4603.
    Campbell R B, Ying B, Kuesters G M. Fighting cancer:from the bench to bedside using second generation cationic liposomal therapeutics [J]. Journal of Pharmaceutical Sciences, 2009(2):411.
计量
  • 文章访问数:  225
  • HTML全文浏览量:  34
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 发布日期:  2013-02-27

目录

    /

    返回文章
    返回
    x 关闭 永久关闭